What guidance did Nuwellis's management provide for the next earnings period?

What were the key takeaways from Nuwellis’s earnings call?

What is the revenue and EPS growth rate for Nuwellis year over year?

Did Nuwellis beat or miss consensus estimates last quarter?

What were the key takeaways from Nuwellis's earnings call?

What factors drove the changes in Nuwellis's revenue and profit?

What does Nuwellis do and what are its main business segments?

What is Nuwellis's gross profit margin?

- **Strategic Restructuring Success**: 2025 transition to cardiorenal focus and operational streamlining drove Q4 revenue growth (+4% YoY) and gross margin expansion to 68.2%.
- **Pediatric Growth Catalyst**: NIH grant and 14% YoY growth in pediatric segment validate long-term clinical value.
- **Rendiatech Integration**: Mid-2026 launch of enhanced ICU fluid management technology to drive utilization in existing accounts.
- **Financial Strength**: $1.2M cash on hand, no debt, and disciplined expense management reducing operating expenses by $0.4M YoY.

**【CEO Summary Section】**
- **2025 Strategic Restructuring**: Revenue declined 5% YoY, but focus shifted to operational efficiency, including manufacturing transition to KDI Precision Manufacturing and exit from unprofitable international markets (e.g., EU). 
- **Cardiorenal Focus**: Reinforced strategy around heart failure and pediatrics, with 8% and 14% YoY growth in these segments. NIH grant for pediatric device development highlights clinical validation.
- **Q4 2025 Results**: Revenue $2.4M (+4% YoY), U.S. console sales up 208%, gross margin 68.2% (vs. 58.4% prior year). Sequential growth driven by catheter utilization.
- **2026 Outlook**: Sales team of 24 focused on Critical Care expansion, with Rendiatech acquisition to enhance fluid management in ICU.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: GAAP net loss $2.4M, but Non-GAAP metrics show progress: 
  - Revenue growth (+4% YoY) driven by higher ASPs and console sales.
  - Gross margin expansion to 68.2% (vs. 58.4% prior year).
  - Operating expenses down $0.4M YoY due to cost control.
- **Full Year 2025**: Revenue $8.3M (-5% YoY), but operating expenses reduced by $0.4M. Ended with $1.2M cash, no debt.
- **2026 Priorities**: Margin consistency, expense discipline, and capital efficiency.

**【Q&A Key Highlights】**
- **Sales Strategy**: 2026 focus on utilization in existing accounts (Critical Care, pediatrics) rather than new geographies. No headcount expansion beyond current 24-person team.
- **Rendiatech Integration**: Acquired technology for urine output measurement in ICU to be integrated with existing fluid management systems, targeting mid-2026 relaunch.
- **Operational Discipline**: 2025 actions (e.g., halting $3M clinical trial, exiting EU) reduced cash burn and strengthened financial position.

Nuwellis, Inc. (NUWE) Q4 2025 Earnings Call Transcript

- **Revenue Mixed but Pro Forma Growth**: Q3 revenue $2.2M (-6% YoY), but pro forma +7% excluding one-time items. Sequential rise 29% driven by consumables and console sales.
- **Product Innovation Driving Adoption**: New 24-hour circuit and dual-lumen catheter expand outpatient use; 92% survival rate in pediatrics highlights clinical impact.
- **Financial Challenges and Strengths**: Gross margin decline to 65.2% due to manufacturing costs, but strong cash position ($3.1M) and $5.9M equity raise support growth.
- **Strategic Shifts**: Exiting international markets, transitioning manufacturing, and advancing outpatient care model to drive long-term growth.

**【CEO Summary Section】**
- **Q3 Momentum and Strategic Focus**: Highlighted progress in critical care, pediatrics, and heart failure with Aquadex therapy adoption. Introduced new 24-hour Aquadex circuit and dual-lumen catheter to enhance flexibility and scalability.
- **Pediatric Innovation**: Advanced Vivien CRRT system development with U.S. patent allowances and 92% survival rate data from ULTRA-Peds registry.
- **Operational Shifts**: Transitioned manufacturing to KDI, exited European operations, and raised $5.9M in equity to support U.S. growth.
- **Outpatient Expansion**: Delivered first Aquadex therapy in hospital-based outpatient setting under new CMS code, signaling proactive care model.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q3 revenue $2.2M (-6% YoY), pro forma growth 7% excluding one-time SeaStar sales. Sequential increase 29% driven by 15% rise in consumables utilization and 4x U.S. console sales.
- **Gross Margin**: 65.2% (vs. 70% YoY) due to under-absorbed fixed overhead; expects margin expansion post-KDI transition.
- **Expense Growth**: Operating expenses $4.1M (+30% YoY) from sales force rebuild and R&D investments. Net income $0.56/share vs. $73.23 prior year (adjusted for reverse split).
- **Liquidity**: $3.1M cash, debt-free, with $5.9M raised in Q3 and June to support 2026 strategy.

**【Closing Remarks】**
- **Future Focus**: Emphasized three growth engines (critical care, pediatrics, outpatient heart failure) and thanked departing CFO Rob Scott for his contributions.

Nuwellis, Inc.(NUWE)-20251112-2025 Q3 Earnings call transcript

- **Q2 revenue decline**: $1.7M (-21% YoY) due to $400K sterilization backorder, now resolved.
- **Pediatrics strength**: +23% YoY growth, Aquadex uniquely approved for <20kg patients.
- **Strategic shifts**: 
  - $4M REVERSE-HF trial termination to fund growth
  - KDI manufacturing transition for cost savings
- **Outpatient opportunity**: 7 hospitals launching clinics with +344% reimbursement rate.
- **Financial health**: $4.5M cash, $12.6M net loss (-40% YoY loss per share).

**【Management Opening Remarks】**
- Nuwellis issued a press release detailing Q2 2025 financial results, with a reminder of forward-looking statement disclaimers.

**【CEO Summary Section】**
- Q2 revenue: $1.7 million (21% YoY decline), impacted by a $400,000 sterilization vendor backorder resolved in early July.
- **Pediatrics growth**: +23% YoY, driven by demand for Aquadex in small children with kidney dysfunction.
- **Critical care adoption**: Increasing use post-cardiac surgery for fluid management.
- **Heart failure focus**: Outpatient clinics leveraging $1,639/day reimbursement, with 7 hospitals setting up programs.
- Strategic moves:
  - Manufacturing transition to KDI Precision (Q4 2025 go-live) for cost savings.
  - Terminated REVERSE-HF trial, reallocating $4 million to high-impact growth areas.

**【CFO Financial Commentary】**
- **Revenue by category**: 
  - Pediatrics: $1.2M (65% of total)
  - Heart Failure: $0.3M (-53% YoY)
  - Critical Care: $0.2M (-35% YoY)
- **Gross margin**: 55.5% (-11.7pts YoY) due to under-absorbed overhead.
- **Operating expenses**: $3.9M (+2% YoY), with R&D up 21% to $0.7M.
- **Net loss**: $12.6M (-40% YoY loss per share), with $4.5M cash and no debt.
- **Capital raise**: $5M gross to support growth initiatives.

**【Q&A Highlights】**
- **Vendor resolution**: Sterilization backorder resolved in early July, inventory replenished.
- **Growth priorities**: 
  - Pediatrics (FDA-cleared for <20kg patients)
  - Cardiac surgery (post-op fluid management)
  - Outpatient heart failure (7 clinics launching)
- **Outpatient focus**: 1st patient treated in July at Prisma Richland, targeting cash flow positive by end-2025.

- **Revenue Resilience**: Q1 2025 revenue up 3% YoY, driven by pediatric and heart failure growth despite critical care volatility.
- **Clinical Validation**: Aquadex reduces heart failure readmissions by 60% in real-world data; new CMS reimbursement boosts outpatient viability.
- **Cost Efficiency**: 31% YoY operating expense reduction to $4.1M; manufacturing outsourcing to cut costs further.
- **Outpatient Expansion**: $773M market opportunity with 4 hospitals launching outpatient clinics this quarter.
- **Pipeline Momentum**: REVERSE-HF trial halfway to enrollment; Vivian trial IDE submission expected late 2025.

**【CEO Opening Remarks】**
- Q1 2025 Revenue: $1.9M (+3% YoY), driven by 4% increase in consumables utilization and U.S. console sales.
- Key Growth Areas: Pediatrics (+38% YoY) and Heart Failure (+28% YoY) due to higher consumable usage.
- Critical Care Decline: 25% YoY drop due to a major customer's inventory buildup; expected normalization in Q2.
- Clinical Momentum: Aquadex shown to reduce heart failure readmissions by 60% in real-world data; new CMS outpatient reimbursement rate (+4x to $1,639/day) expands market access.
- Outpatient Strategy: Targeting $773M addressable market with 4 hospitals preparing to launch outpatient clinics this quarter.
- Tariff Resilience: Minimal international raw material reliance; no material impact from tariffs.

**【CFO Financial Highlights】**
- Gross Margin: 56% (vs. 64.1% YoY), down due to manufacturing variances and inventory adjustments.
- Operating Expenses: $4.1M (-31% YoY), with SG&A down 22% to $3.6M and R&D down 58% to $0.55M.
- Cash Position: $2.6M; no debt; focused on disciplined expense management.

**【Q&A Key Takeaways】**
- Pediatric Growth Sustainability: 2 new hospital accounts added; Aquadex uniquely suited for low blood volume pediatric cases.
- Outpatient Rollout Timeline: 4 hospitals launching Q2; expect meaningful revenue contribution from Q3 onward.
- Clinical Trial Progress: REVERSE-HF trial halfway to 372 patient enrollment; Vivian trial IDE submission expected late 2025.
- Cost Optimization: Manufacturing outsourcing to KDI expected to reduce expenses over next 12 months.

Nuwellis (NUWE)-13 May 25-2025 Q1 Earnings call transcript

- **Revenue resilience**: -9% YoY decline offset by +21% consumables growth, signaling clinical adoption.
- **Outpatient opportunity**: 4x reimbursement increase unlocks $1.6M/day revenue potential in new market.
- **Clinical validation**: Landmark JACC study validates Aquadex as superior to IV diuretics in heart failure.
- **Financial strength**: 81% YoY net loss reduction to $1.5M; $5.1M cash runway with no debt.

**【CEO Summary Section】**
- Q4 2024 revenue: $2.3 million (-9% YoY), driven by -21% console sales offset by +21% consumables utilization.
- Key wins: 9 new accounts in 2024, including 2 pediatric hospitals.
- Outpatient market expansion: CMS reimbursement increased 4x to $1,639/day effective Jan 2025, enabling new outpatient programs.
- Clinical evidence milestone: JACC:HF study showed Aquadex reduced heart failure events by 60% vs IV diuretics.

**【CFO Financial Commentary】**
- Gross margin improved to 58.4% (vs 54.4% YoY) due to higher consumables volumes.
- SG&A expenses down 19% to $2.9M, R&D down 42% to $0.8M, total opex -25% to $3.7M.
- Net loss narrowed to $1.5M (-81% YoY) due to cost cuts and $0.9M one-time gain.
- Cash balance: $5.1M with no debt.

**【Q&A Highlights】**
- Outpatient traction: Early-stage discussions with existing accounts to establish outpatient facilities.
- Q4 console sales: 3 units (vs 11 in Q3 2024).
- Clinical trials: Enrollment ongoing for Reverse HF and Vivian trials; timing uncertain.
- CEO search: Active with search firm; candidates identified but no timeline.

Actual												-1631700	-441000	-305760	-166110	-183750	-105840	-110250	-60270	-61740	-60270	-54390	-7350	-8467.2	-5365.5	-2660.7	-3292.8	-882	-791.7	73.08	-18.48	-28.98	-60.99	0.56	-1.5
Forecast												-3439800	-815850	-269010	-280770	-170520	-130830	-107800	-70070	-63700	-62720	-47040	-120691.9	-5576.2	-5914.3	-4577.972	-2043.3	-1558.2	-346.29	-53.76	-18.06	-18.9	-18.9	-17.22	-1.56
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+52.56%	+45.95%	-13.66%	+40.84%	-7.76%	+19.10%	-2.27%	+13.99%	+3.08%	+3.91%	-15.63%	+93.91%	-51.85%	+9.28%	+41.88%	-61.15%	+43.40%	-128.62%	+235.94%	-2.33%	-53.33%	-222.70%	+103.25%	+3.85%

Actual	--	--	--	--	--	--	--	--	--	--	--	1.63M	1.86M	1.90M	2.04M	1.92M	2.51M	1.85M	1.64M	1.93M	2.21M	2.06M	2.34M	1.83M	2.08M	2.41M	2.55M	1.86M	2.19M	2.37M	2.32M	1.90M	1.73M	2.22M	2.42M
Forecast	--	--	--	--	--	--	--	--	--	--	--	1.57M	1.77M	2.13M	2.06M	2.06M	2.08M	2.24M	2.11M	1.78M	2.10M	2.29M	2.21M	2.34M	2.19M	2.29M	2.57M	2.00M	2.00M	2.36M	2.46M	2.50M	2.20M	2.50M	2.31M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+3.82%	+4.96%	-10.82%	-0.85%	-6.87%	+20.81%	-17.13%	-22.24%	+8.49%	+5.28%	-9.88%	+6.08%	-22.08%	-5.12%	+5.53%	-0.65%	-7.20%	+9.54%	+0.38%	-5.67%	-23.84%	-21.59%	-11.32%	+4.94%

NUWE

NUWE fundamentals

NUWE Q4 2025 Earnings

Earnings Call

You can ask Aime

NUWE

NUWE fundamentals

NUWE Q4 2025 Earnings

Earnings Call

NUWE Earnings Call Summary for Q4/20259:00 AM on Mar 10, 2026

NUWE Earnings Call Summary for Q3/20259:00 AM on Nov 12, 2025

NUWE Earnings Call Summary for Q2/20259:00 AM on Aug 12, 2025

NUWE Earnings Call Summary for Q1/20259:00 AM on May 13, 2025

NUWE Earnings Call Summary for Q4/20249:00 AM on Mar 11, 2025

You can ask Aime